on behalf of the ASA-STAT Study Group Background-Pulmonary arterial hypertension (PAH) is a progressive disease that causes exercise limitation, heart failure, and death. We aimed to determine the safety and efficacy of aspirin and simvastatin in PAH. Methods and Results-We performed a randomized, double-blind, placebo-controlled 2ϫ2 factorial clinical trial of aspirin and simvastatin in patients with PAH receiving background therapy at 4 centers. A total of 92 patients with PAH were to be randomized to aspirin 81 mg or matching placebo and simvastatin 40 mg or matching placebo. The primary outcome was 6-minute walk distance at 6 months. Sixty-five subjects had been randomized when the trial was terminated by the Data Safety and Monitoring Board after an interim analysis showed futility in reaching the primary end point for simvastatin. After adjustment for baseline 6-minute walk distance, there was no significant difference in the 6-minute walk distance at 6 months between aspirin (nϭ32) and placebo (nϭ33; placebo-corrected difference Ϫ0.5 m, 95% confidence interval Ϫ28.4 to 27.4 m; Pϭ0.97) or between simvastatin (nϭ32) and placebo (nϭ33; placebo-corrected difference Ϫ27.6 m, 95% confidence interval Ϫ59.6 to 4.3 m; Pϭ0.09).
visualized circulating platelet aggregates in the blood of patients with PAH, 10 and increased platelet aggregation is associated with more severe PAH. 11 Soluble P-selectin is elevated in patients with PAH, and platelet-released CD40 ligand increases across the pulmonary vascular bed, which suggest transpulmonary platelet activation. 12, 13 Thrombocytopenia due to platelet trapping in the lungs occurs during PAH crises 14, 15 and is associated with worse hemodynamics. 16 Aspirin lowers the Tx-PGI 2 ratio in PAH (even in patients chronically treated with PGI 2 analogues or other medications) and inhibits platelet activity, 2 thereby offering a potential therapeutic approach. A recent study showed that aspirin decreased pulmonary artery pressure, reduced right ventricular hypertrophy, and improved survival in the monocrotaline animal model of pulmonary hypertension. 17 Reductions in nitric oxide production and endothelial nitric oxide synthase activity and increases in oxidative stress contribute to endothelial dysfunction in patients with PAH. 18, 19 Statins inhibit proliferation, induce apoptosis, and cause vasorelaxation in vascular smooth muscle cells, enhance expression and activity of endothelial nitric oxide synthase in endothelium, and reduce oxidative stress and inflammation. 20 -24 Several studies have demonstrated the efficacy of statins in animal models of pulmonary hypertension. [25] [26] [27] [28] [29] [30] [31] [32] Uncontrolled human studies of simvastatin have also suggested benefit in patients with PAH. 33, 34 One recently published randomized clinical trial (RCT) showed that simvastatin decreased right ventricular mass and plasma N-terminus probrain natriuretic peptide (NT-proBNP), but had no effect on 6-minute walk distance (6MWD) in patients with PAH. 35 Aspirin and simvastatin have potential for the treatment of PAH by targeting platelet activation and endothelial dysfunction. We aimed to show the feasibility of studying these therapies and to obtain estimates of efficacy and safety in a phase II RCT. We hypothesized that the 6MWD at 6 months would be greater in subjects with PAH assigned to aspirin or simvastatin than to the respective placebo after adjustment for baseline 6MWD.
Methods

Study Design
ASA-STAT was a 4-center, randomized, double-blind, placebocontrolled 2ϫ2 factorial study to determine the efficacy and safety of aspirin and simvastatin in patients with PAH. Details of the methods have been published elsewhere 36 (see the online-only Data Supplement). The initial protocol called for the recruitment of 128 subjects with PAH (with the anticipation of having 100 subjects complete the study) over approximately 3 years. The first patient was randomized in January 2007, and a total of 65 patients were randomized by September 2009, when the study was terminated (see below).
The trial protocol was approved by the institutional review board at each participating center and by the Data Safety and Monitoring Board (DSMB). The trial was registered at clinicaltrials.gov before recruitment was initiated (NCT00384865).
Study Participants
We included patients Ͼ18 years of age with PAH without an indication for aspirin or statin therapy and without risk factors for adverse events from these medications (online-only Data Supplement Table I 
Study Procedures
Patients were identified by medical staff. Subjects were randomly assigned in a 1:1:1:1 ratio by a Web-based computerized system to enteric coated aspirin 81 mg (Tiny Tablets, Bayer HealthCare LLC, Morristown, NJ) once daily/simvastatin 40 mg (Zocor, Merck & Co, Whitehouse Station, NJ), aspirin 81 mg once daily/simvastatin placebo once daily, aspirin placebo once daily/simvastatin 40 mg once daily, or aspirin placebo once daily/simvastatin placebo once daily. The randomization scheme was random permuted block, stratified by type of PAH (idiopathic/heritable versus other) and center. All subjects and study personnel (other than the Data Coordinating Center Chair and research pharmacy) were masked to treatment assignment and were not unmasked until the study was completed. Subjects were evaluated at baseline, 6 weeks, 3 months, and 6 months. 36 The primary outcome was 6MWD at 6 months after randomization after adjustment for baseline 6MWD. Secondary outcomes included 6MWD, measures of platelet activation (serum TxB 2 , plasma ␤-thromboglobulin, and soluble P-selectin levels) and endothelial function (brachial artery flow-mediated dilation and plasma von Willebrand factor levels), NT-proBNP levels, C-reactive protein levels, oxidized low-density lipoprotein (LDL) levels, World Health Organization functional class, Borg dyspnea score, and Short Form-36 (SF-36) scores at 6 weeks, 3 months, and 6 months after randomization. We assessed time to clinical worsening (defined by the addition of new PAH therapies or dose increases in previously stable PAH therapy, hospitalization for right-sided heart failure, lung transplantation, atrial septostomy, and cardiovascular and all-cause death). End-point and bleeding definitions and details of end-point assessments are provided in the online-only Data Supplement and in Kawut et al. 36 
Study Monitoring
Details of study monitoring are provided in the online-only Data Supplement and in Kawut et al. 36 The enrollment period lasted from January 2007 to September 2009. In July 2009, the DSMB requested a conditional power calculation by the Data Coordinating Center using the subjects enrolled to that point. This showed that the trial had a 4.9% chance of detecting a statistically significantly higher 6MWD for simvastatin than for placebo. The DSMB determined that continuing the study with only the aspirin-versus-placebo comparison would lead to a study with low scientific credibility, and they recommended study termination. The DSMB recommended that subjects currently active in the trial at that time (nϭ16) should discontinue receiving all study drugs and should not be followed up or undergo any additional study procedures. The DSMB reported that there were no significant safety concerns related to the recommendation for termination. The National Heart, Lung, and Blood Institute accepted these recommendations, and active subjects stopped taking study medications and did not return to the field centers or have telephone follow-up after September 25, 2009.
Statistical Analysis
The primary end point of the trial was 6MWD at 6 months after randomization, after adjustment for baseline 6MWD. Preliminary data suggested that a difference of Ͼ50 m in 6MWD was associated with an improvement in symptoms and survival. A total of 100 subjects (25 in each of the 4 randomized groups, 50 in each active drug and placebo group) was necessary to detect a difference of 57 m with 80% power, with the assumption of no significant interaction between study drugs and without adjustment for baseline 6MWD. With a significant interaction between study medications, we had 80% power to detect a difference of 80 m. Anticipating 20% attrition, we initially planned for the enrollment of 128 subjects. In May 2009, the DSMB requested revised sample size calculations (online-only Data Supplement). The revised sample size of 92 was approved by the DSMB and National Heart, Lung, and Blood Institute on June 4, 2009.
The primary analysis proceeded according to the intention-to-treat principle. Hypothesis testing for the primary and secondary end points was conducted with 2-sided ␣ϭ0.05. There was no observed clinically relevant statistical interaction between the study medications (see protocol in the online-only Data Supplement and in Kawut et al. 36 ) so all analyses proceeded at the margins by comparing patients assigned to aspirin with those who were assigned to aspirin placebo, and by comparing those assigned to simvastatin with those who were assigned to simvastatin placebo.
Continuous variables are presented as meanϮSD or median (interquartile range) and categorical variables as n (%). Skewed variables were natural log transformed before analysis. The analysis of the primary end point compared the absolute 6MWD at 6-month follow-up between active-therapy and placebo groups with adjustment for baseline 6MWD by use of linear regression models. Multiple imputation was performed for subjects without a 6-month 6MWD in the primary analysis (see online-only Data Supplement for details). Secondary analyses incorporated all of the available endpoint assessments (6 weeks, 3 months, and 6 months) without imputation in linear mixed-effects models with adjustment for baseline values. There were no interim analyses or stopping rules planned a priori for the trial. Other analyses are described in the online-only Data Supplement and in Kawut et al. 36 
Results
We screened 712 PAH patients during the enrollment period from January 2007 to September 25, 2009 . Of the adjusted target sample of 92, 65 were randomized, and 49 had completed the 6-month assessment at study termination (3 died, 1 withdrew consent, and 12 were active in the trial and had not yet had their 6-month study visits; Figure 1 ). One subject completed the study, but was unable to perform the walk at the 6-month assessment. At study termination, 59 of the 65 randomized subjects had undergone at least 1 outcome assessment.
The mean age of the participants was 50.5Ϯ13.9 years, and 56 (86.1%) were women. Thirty-nine (60.0%) were non-Hispanic white, 9 (13.9%) were Hispanic, 13 (20.0%) were black, and 3 (4.6%) were Asian. Thirty-three (51.6%) had idiopathic PAH, 3 (4.7%) had heritable PAH, 12 (18.8%) had PAH associated with systemic sclerosis, 9 (15.3%) had PAH associated with other connective tissue diseases, and 6 (9.2%) had congenital systemic-to-pulmonary shunts. Those enrolled were somewhat younger, but similar in terms of sex and race, than those screened and not enrolled (Table II, 
Aspirin Versus Placebo
Thirty-two subjects were randomized to aspirin, and 33 were randomized to placebo ( Table 1 ). The 2 groups were similar in terms of demographics. Subjects randomized to aspirin had a somewhat higher prevalence of idiopathic/heritable PAH than other forms, more frequent use of sildenafil, somewhat lower World Health Organization functional class, and somewhat higher baseline 6MWD. Combination therapy was common, and most patients were treated with warfarin. Six subjects discontinued the aspirin study drug (2 aspirin, 4 placebo; Figure 1 ). One participant was started on nonstudy aspirin after she was diagnosed with coronary artery disease. One patient stopped taking the aspirin study drug because of epigastric pain, 1 had a decrease in hemoglobin without clinical bleeding, 1 had a new gastric ulcer with bleeding, 1 had light-headedness, and 1 stopped without providing a reason. Compliance with the study drug was Ͼ95%.
There was no difference in 6MWD between aspirin and placebo groups at 6 months after adjustment for baseline 6MWD (least squares means: 438.0 m, 95% confidence interval [CI] 415.9 to 460.1 m versus 438.5 m, 95% CI 419.2 to 457.8 m, respectively; Pϭ0.97; nϭ65). The placebocorrected difference in 6MWD at 6 months was Ϫ0.5 m (95% CI Ϫ28.4 to 27.4 m). Median postwalk Borg dyspnea scores at 6 months were similar between the groups (aspirin 3 [interquartile range 2 to 4] versus placebo 3 [interquartile range 2 to 4], Pϭ0. 39) . Analyses that included the 6MWD from all postrandomization visits without imputation after adjustment for baseline showed similar results (Figure 2A ).
Aspirin reduced serum TxB 2 levels by 93% compared with placebo ( Figure 2B ), which suggests that the study drug had the expected effect on eicosanoid metabolism. However, there were no differences in soluble P-selectin, ␤-thromboglobulin, or NT-proBNP levels between the groups (Figure I A-C, onlineonly Data Supplement). There were no differences in any scales of the SF-36 (Table III , online-only Data Supplement) or in World Health Organization functional class (data not shown).
All clinical worsening events are shown in Table IV in the online-only Data Supplement. Subjects receiving aspirin had 2 clinical worsening events and subjects receiving placebo had 6 (Pϭ0. 19 ). There was no difference in time to clinical worsening between the groups (Pϭ0.35; Figure II , onlineonly Data Supplement).
We performed prespecified subset analyses in patients with baseline 6MWD Ͻ450 m (nϭ32); there were no differences in the results from the full sample (data not shown). In Data are shown as meanϮSD, median (interquartile range), or n (%). patients with idiopathic or heritable PAH, we found that aspirin may have lowered soluble P-selectin levels (Pϭ0.07) but did not have an impact on the 6MWD (Figure III , online-only Data Supplement). Other results were similar to those from the main analysis (data not shown). Adverse events in the aspirin and placebo groups are shown in Table 2 . There were no differences in the numbers of minor bleeding episodes (Pϭ0.87) between the groups, but there may have been an increase in major bleeding episodes in subjects treated with aspirin (Pϭ0.17). There were no differences in safety laboratory results between the groups (data not shown).
Simvastatin Versus Placebo
Thirty-two subjects were randomized to simvastatin and 33 to placebo ( Table 3 ). The 2 groups were similar in terms of demographics and type of PAH. Patients randomized to simvastatin had somewhat higher right ventricular systolic pressure by transthoracic echocardiography, but World Health Organization functional class and 6MWD at baseline were similar between the groups. More than 60% of both groups were treated with sildenafil either as monotherapy or in combination therapy. Five subjects discontinued the simvastatin study drug (2 simvastatin, 3 placebo; Figure 1 ). One participant was diagnosed with coronary artery disease, and pravastatin was prescribed. Two patients discontinued the study drug for myalgias, 1 for headaches, and 1 without providing a reason. Compliance with the study drug was Ͼ95%.
There was no difference in 6MWD between simvastatin and placebo groups at 6 months after adjustment for baseline 6MWD (least squares means 425.0 m, 95% CI 400.2 to 449.9 m versus 452.7 m, 95% CI 431.9 to 473.4 m, respectively; Pϭ0.09; nϭ65), with a placebo-corrected difference in 6MWD of Ϫ27.6 m (95% CI Ϫ59.6 to 4.3 m), which indicates that simvastatin may have reduced the 6MWD. Additionally, median postwalk Borg dyspnea scores at 6 months tended to be higher in the subjects assigned to simvastatin, which suggests greater breathlessness (simvastatin 3 [interquartile range 2 to 4] versus placebo 3 [interquartile range 2 to 4]; Pϭ0.07). Analyses that included the 6MWD from all postrandomization visits without imputation after adjustment for baseline 6MWD were also consistent with lower 6MWD in the group randomized to simvastatin ( Figure 3A) .
Simvastatin significantly decreased total cholesterol, LDL, and oxidized LDL levels (Figures 3B-D) compared with placebo but did not affect triglycerides or high-density lipoprotein levels ( Figures IV A-B , online-only Data Supplement), consistent with the expected effects. However, there were no differences in levels of von Willebrand factor, C-reactive protein, or NT-proBNP or in flow-mediated dilation between the groups (Figures V A-D , online-only Data Table VI in the online-only Data Supplement. Subjects receiving simvastatin and subjects receiving placebo each had 4 events (Pϭ0.33). There was no difference in time to clinical worsening between the groups (Pϭ0.80; Figure VI , online-only Data Supplement).
We performed prespecified subset analyses in patients with baseline 6MWD Ͻ450 m (nϭ32); there were no differences in the results from the full sample (data not shown). In patients with idiopathic or heritable PAH, we found that simvastatin did not have an impact on the 6MWD ( Figure  VII , online-only Data Supplement). Other results were similar to those from the main analysis (data not shown).
Adverse events in the simvastatin and simvastatin placebo groups are shown in Table 4 . There was no difference in adverse events between the groups. There were no differences in safety laboratory results between the groups (data not shown).
Discussion
This is the first RCT of traditional cardiovascular disease therapies targeting platelet and endothelial function and the first National Institutes of Health-funded RCT in patients with PAH. Neither aspirin nor simvastatin had a significant effect on the primary end point of 6MWD at 6 months. If anything, 6MWD may have decreased, and postwalk Borg dyspnea scores increased, with simvastatin. Although aspirin lowered serum TxB 2 levels, other traditional markers of platelet activation such as soluble P-selectin levels (except possibly in idiopathic/heritable PAH) and ␤-thromboglobulin were not altered. There was a possible increased risk of major bleeding associated with aspirin use. Although simvastatin lowered total cholesterol and LDL levels, there was no effect on other vascular or plasma markers of endothelial dysfunction or injury (flow-mediated dilation and von Willebrand factor) or C-reactive protein. Simvastatin significantly lowered oxidized LDL levels, which reflect oxidative stress. Neither aspirin nor simvastatin affected NT-proBNP levels. The effects of aspirin and simvastatin on serum TxB 2 and lipid levels, respectively, provided evidence that subjects were compliant with the study medication and that the medications had their traditional effects in patients with PAH. Early termination of the trial because of futility in detecting a positive effect of simvastatin on the 6MWD limited the power of some analyses; however, none of the point estimates for the end points suggested a benefit, and the precision of the estimates of 6MWD was good, which makes it less likely that low power accounted for the results. Aspirin reduced production of Tx both in the present study and in our previous study in idiopathic PAH, in which platelet aggregation was also significantly inhibited by low-dose aspirin. 2 Because the Tx-PGI 2 ratio is elevated in PAH and platelet aggregation is thought to contribute to disease pathogenesis, it was hypothesized that platelet inhibition with aspirin would translate to clinical benefit in terms of exercise capacity. Although aspirin suppressed production of TxB 2 by Ͼ90%, there was no effect on 6MWD, NT-proBNP, or quality of life. This suggests that platelet Tx production does not contribute significantly to disease manifestations in PAH. One previous trial of a Tx synthase inhibitor was performed in PAH, 37 but it was terminated prematurely because of an excess of side effects (leg pain) and it did not show a clinical benefit.
Although aspirin did lower serum TxB 2 , the effect was somewhat less than the 97% to 99% TxB 2 suppression usually seen with aspirin. 38 This suggests either aspirin resistance or another source of Tx unaffected by low-dose aspirin (eg, vascular endothelium). The lack of change of ␤-thromboglobulin levels and the borderline reductions in soluble P-selectin levels are also consistent with aspirin resistance. Ongoing vascular injury could also account for the smaller impact of aspirin on soluble P-selectin levels than seen in healthy individuals.
There were no differences in health-related quality of life with aspirin. There tended to be fewer clinical worsening events in the aspirin group, but there was also a somewhat higher incidence of major bleeding events. We were unable to assess the interaction of aspirin with warfarin because of the small number of events.
Simvastatin has a significant effect on pulmonary vascular disease and right ventricular changes in a variety of animal models. We have shown that statins have an impact on pulmonary hypertension and vascular remodeling in the chronically hypoxic rat model. 25, 31, 39 Other studies have reproduced these findings in the monocrotaline animal model, but not universally. 26, 40, 41 There have been 2 previous small RCTs of statins in patients with PAH. One studied the effect of rosuvastatin in patients with PAH that was idiopathic or associated with congenital heart disease. 42 There were no statin-associated differences in 6MWD or other biomarkers. Wilkins et al 35 performed a placebo-controlled, double-blind RCT of simvastatin in 43 patients with PAH that was idiopathic, heritable, or associated with atrial septal defect or connective tissue disease. Simvastatin significantly reduced right ventricular mass and plasma NT-proBNP at 6 months, changes that were not maintained at 1 year. Notably, there was no effect of simvastatin on 6MWD, other right ventricular parameters, quality of life, or other biomarkers.
In the present study, simvastatin did not improve 6MWD, biomarkers of endothelial dysfunction and injury, or quality of life. If anything, there were trends toward decreased 6MWD and more dyspnea in patients randomized to simvastatin. These results suggest that simvastatin is not effective as add-on therapy in PAH. Systemic side effects, such as myalgia and arthralgia, could have had an impact on the measured response to the study medication; however, an increasing Borg dyspnea score after the 6-minute walk suggested respiratory limitation.
Studying PAH patients receiving background therapy makes it more difficult to conduct trials of new therapies focused on clinically meaningful end points within a reasonable period of time. Because patients in clinical trials must receive the standard of care, this is the only ethically justifiable approach to intermediate or long-term placebocontrolled trials in the era of available effective therapy.
The present study has several limitations. The primary end point that should be used in early-stage clinical trials in PAH is uncertain. We chose the 6MWD because it is the one by which all PAH therapies have been approved; an effective treatment should show some signal in terms of this measure. Available therapies for PAH that increase the 6MWD often improve long-term clinical outcomes, although 6MWD has not been validated as a surrogate end point. 43 However, it remains possible that the active treatment had some favorable effect that went undetected. The development and validation of surrogate end points that change over a short period of time and reliably predict clinically meaningful outcomes is an unmet need in the field.
We did not include invasive hemodynamic end points. Measurement of pulmonary hemodynamics as a secondary outcome would have been of interest, but for pragmatic reasons, it could not be done. The requirement for multiple right-sided heart catheterizations on otherwise stable, treated patients would have rendered the recruitment much more difficult and the study much more expensive, making the trial infeasible. Although there is no specific biomarker readout for pulmonary vascular function, the absence of any effect of the study drugs on NT-proBNP suggests that there was no impact on hemodynamics. Whether either agent had other long-term benefits beyond 6 months was not assessed.
The present study was terminated because of a high likelihood of not rejecting the null hypothesis for the simvastatin arm even if fully recruited. Subjects were not followed up or reassessed after study termination, which led to missing data for those active subjects in the trial at termination (nϭ16). These missing data may have introduced bias, even though such data should be missing completely at random. The results and conclusions were similar whether we multiply imputed missing data or performed analyses with only the available data, which makes significant bias less likely. Although even effective drugs may have a reduced impact in the setting of background therapy in PAH, simvastatin was associated with a decrease in 6MWD, and there was essentially no change in 6MWD with aspirin, which makes inadequate power an unlikely explanation for the present results. Results from the subgroup with idiopathic PAH and heritable PAH did not differ from those of the main study; other disease subgroups were not large enough for meaningful analyses.
In summary, we have shown that, although simvastatin 40 mg each day lowered total cholesterol, LDL, and oxidized LDL, there was no effect on 6MWD or biomarkers of endothelial dysfunction or injury in PAH. Similarly, although aspirin 81 mg each day reduced TxB 2 production and may have lowered soluble P-selectin levels (in idiopathic or heritable PAH), there was no effect on 6MWD, and it possibly increased the risk of major bleeding. On the basis of these findings, neither drug can be recommended for the treatment of PAH. These drugs should be used according to usual indications in PAH.
